Healthcare - Press Releases

SIRUM's pharmacy service, Good Pill Pharmacy, will offer 500+ low-cost medications to anyone in Maryland whose medication costs are too high

RANCHO CUCAMONGA, Calif., March 13, 2025 /PRNewswire/ -- Inland Empire Health Plan (IEHP), the California Community College system and the San Bernardino Community College District (SBCCD) are partnering to connect local college students to low-cost, high-quality health care and CalFresh programs. Known as the Inland Empire Health Plan Equitable Support Demonstration Project, the collaboration is the first of its kind and will serve as a pilot program for other counties across the state.

LINKPING,Sweden, March 14, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's(STO: SECT B) enterprise imaging module for radiology is ranked number one by users around the world. We also have the most satisfied customers in digital pathology. Our commitment to customer satisfaction is the foundation of our success in all operating areas. The operating profit trend for the Group is positive despite the ongoing transition to service sales. A settlement was also reached in the third quarter regarding Sectra's patented technology for secure communication, which had a positive non-recurring effect on the Group's financial outcomes.

LINKPING,Sweden, March 14, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's(STO: SECT B) enterprise imaging module for radiology is ranked number one by users around the world. We also have the most satisfied customers in digital pathology. Our commitment to customer satisfaction is the foundation of our success in all operating areas. The operating profit trend for the Group is positive despite the ongoing transition to service sales. A settlement was also reached in the third quarter regarding Sectra's patented technology for secure communication, which had a positive non-recurring effect on the Group's financial outcomes.

NEW YORK and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the closing of its $12 million Series B Plus financing. The round was led by Shenzhen Capital Group (SCGC), an existing investor, with participation from Morningside Ventures, also an existing investor, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST).

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective was to assess ifblue light cystoscopy (BLC) aided TURBT has an impact on the clinical outcomes of patients with NMIBC*. Results of the real-world evidence study show that BLC was associated with a statistically significant 38% reduction in risk of recurrence compared to white light cystoscopy (WLC) use alone in a predominantly high-risk NMIBC patient cohort. These results are in line with prior results from multiple randomized controlled clinical trials.

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective was to assess ifblue light cystoscopy (BLC) aided TURBT has an impact on the clinical outcomes of patients with NMIBC*. Results of the real-world evidence study show that BLC was associated with a statistically significant 38% reduction in risk of recurrence compared to white light cystoscopy (WLC) use alone in a predominantly high-risk NMIBC patient cohort. These results are in line with prior results from multiple randomized controlled clinical trials.

American Association of Kidney Patients (AAKP)

SUNNYVALE, Calif., March 13, 2025 /PRNewswire/ --Imagine finishing your last appointment of the day and heading straight home-no staying late for charting, and no missing precious family moments. Dr.Vinni K. Singh envisioned exactly that when she developed DentScribe, the AI-powered dental documentation and patient communication agentic system. Built by a dentist for dentists, DentScribe transforms how dental professionals manage documentation, follow-ups, and patient interactions.

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader approvals for early-stage treatment all contribute to its promising growth potential.

KING OF PRUSSIA, Pa., March 11, 2025 /PRNewswire/ -- Universal Health Realty Income Trust (NYSE:UHT) announced today that its Board of Trustees voted to pay a dividend of $.735 per share on March 31, 2025 to shareholders of record as of March 24, 2025.

Pilot projects in Maryland, New York, North Carolina, Texas, and Utah to address high rates of food insecurity and diet-related diseases among U.S. Veterans

HONG KONG, March 11, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in Australia in healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C) (Part I) and in patients with obesity (Part II) (NCT06427590).

ALEXANDRIA, Va., March 11, 2025 /PRNewswire/ -- Statement Attributable to:Courtney Bugler, CEO, ZERO Prostate Cancer

Top-20-Biopharma nutzt die Veeva Development Cloud, um die Entwicklung von Therapien fr derzeit unheilbare Krankheiten zu beschleunigen

The Ultra low-power BG29 SoC can use a range of different battery compositions to match the energy needs of connected devices. The small size and high-performance of the BG29 SoC is ideal for the demanding needs of small form-factor wearables. (PRNewsfoto/Silicon Labs)

RAICHUR, India, March 12, 2025 /PRNewswire/ --Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug (IND) - Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg - and recommended marketing authorization for treating non-alcoholic fatty liver disease (NAFLD).

RAICHUR, Inde, 12 mars 2025 /PRNewswire/ --Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), l'un des principaux fabricants d'IPA et de formulations, annonce que le comit d'experts du domaine (SEC) de la CDSCO a approuv son nouveau mdicament exprimental (IND), acide nor-ursodsoxycholique (norUDCA) en comprims de 500mg, et a recommand une autorisation de mise sur le march pour le traitement de la statose hpatique non alcoolique (NAFLD).

- lanc Therapeutics aims to improve current obesity treatment, specifically to increase overall body weight loss and fat mass loss, but preserve and even increase muscle and lean mass- lanc Therapeutics will leverage HCAb-based bispecific antibody technology to advance these next-generation therapies- lanc will refine and expand Hu-mAtrIxTM AI platform to empower multiple bispecific antibody discovery programs

PROSIDIUM debuts as a novel solution to control pathogens that can lead to foodborne illnesses, including viral challenges in poultry and swine production

Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth.

BELLEVUE, Wash., March 12, 2025 /PRNewswire/ --Aegis Living, a premier leader in senior assisted living and memory care services, is proud to announce the appointment of Richard Galanti and Ally Svenson to its Advisory Board. These distinguished additions bring a wealth of experience and visionary leadership that will further strengthen Aegis Living's commitment to excellence in senior care.

STOCKHOLM, March 12, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pr Gellerfors, as well as the company's CEO, Gunilla Osswald, have been awarded the university's Innovation and Entrepreneurship Prize for successfully addressing a growing global health problem.

STOCKHOLM, March 12, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pr Gellerfors, as well as the company's CEO, Gunilla Osswald, have been awarded the university's Innovation and Entrepreneurship Prize for successfully addressing a growing global health problem.

Advancing Scientific Recognition in Non-Surgical Fat Reduction